CalciMedica (CALC) Operating Income (2019 - 2026)
CalciMedica's (CALC) quarterly Operating Income came in at -$5.6 million in Q1 2026, up 13.64% YoY from -$4.9 million in Q1 2025, and down 27.96% on a QoQ basis from -$4.4 million in Q4 2025.
CalciMedica (CALC) Operating Income (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Operating Income data on file, last reported at -$5.6 million in Q1 2026.
- Quarterly Operating Income rose 13.64% year-over-year to -$5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.2 million (up 10.82% YoY) and the FY2025 annual result came in at -$23.1 million, up 4.47% from the prior year.
- Operating Income slipped to -$5.6 million in Q1 2026, from -$4.4 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$3.1 million in Q4 2022 to a low of -$22.3 million in Q1 2023.
- A 5-year average of -$6.2 million and a median of -$5.6 million in 2025 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2023 — Operating Income sank 430.52% — and 2024, when it jumped 74.19%.
- Tracing CALC's Operating Income over 5 years: stood at -$3.1 million in 2022, then slumped by 39.1% to -$4.3 million in 2023, then sank by 42.9% to -$6.2 million in 2024, then increased by 28.95% to -$4.4 million in 2025, then slipped by 27.96% to -$5.6 million in 2026.
- The last three Operating Income figures came in at -$5.6 million (Q1 2026), -$4.4 million (Q4 2025), and -$5.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | CalciMedica | 9.93 Mn | -8.69 Mn | - | -4.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.01 Mn |
| Mar 31, 2026 | -5.61 Mn |
| Dec 31, 2025 | -4.39 Mn |
| Sep 30, 2025 | -5.62 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -6.17 Mn |
| Sep 30, 2024 | -5.74 Mn |
| Jun 30, 2024 | -6.53 Mn |
| Mar 31, 2024 | -5.77 Mn |
| Dec 31, 2023 | -4.32 Mn |
| Sep 30, 2023 | -4.83 Mn |
| Jun 30, 2023 | -6.58 Mn |
| Mar 31, 2023 | -22.34 Mn |
| Dec 31, 2022 | -3.11 Mn |
| Sep 30, 2022 | -3.29 Mn |
| Jun 30, 2022 | -3.59 Mn |
| Mar 31, 2022 | -4.21 Mn |
| Dec 31, 2021 | -8.70 Mn |
| Sep 30, 2021 | -8.02 Mn |